MAPT and Alzheimer disease: For example, Zhang et al. [123] showed that combining molecular imaging (volumetric MRI, Pittsburgh Compound-B (PIB)- & FDG-PET and CSF-t-tau, -p-tau and -Aβ42 biomarkers) as reported by Fjell et al.[124] would achieve a higher diagnostic accuracy when discriminating between AD (93.2%) and MCI (76.4%) with healthy patients as well as 91.5% MCI converters and 73.4% MCI nonconverters correctly classified.